



(51) International Patent Classification:

A61K 31/366 (2006.01) *A61K 31/351* (2006.01)
A61K 31/365 (2006.01) *C12N 5/09* (2010.01)

(21) International Application Number:

PCT/US2020/033638

(22) International Filing Date:

19 May 2020 (19.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/850,905 21 May 2019 (21.05.2019) US

(71) Applicant: **THE BOARD OF TRUSTEES OF THE LE-
LAND STANFORD JUNIOR UNIVERSITY** [US/US];
Office of the General Counsel, Building 170, 3rd Floor,
Main Quad, P.O. Box 20386, Stanford, California 94305
(US).


(72) Inventors: **WENDER, Paul**; 337 Campus Drive, Mail Post
5080, Stanford, California 94305 (US). **SHIMIZU, Akira
J.**; 87 Hulme Court, Apt. 418, Stanford, California 94305
(US). **HARDMAN, Clayton**; 337 Campus Drive, Mail Post
5080, Stanford, California 94305 (US).

(74) Agent: **NG, Rudy**; Bozicevic, Field & Francis LLP, 201
Redwood Shores Pkwy, Suite 200, Redwood City, Califor-
nia 94065 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: BRYOSTATIN COMPOUNDS FOR ENHANCEMENT OF IMMUNOTHERAPY



(see FIG. 1, panel d)

FIG. 1

(57) **Abstract:** Provided herein is the use of bryostatin agents to se-
lectively enhance expression, translocation and/or cell surface pre-
sentation of an antigen in target cells of interest to modulate im-
munogenicity of the target cells. Aspects of the methods include,
administering an effective amount of a bryostatin agent to a subject
to modulate immunogenicity of target cells. The subject methods in-
clude a method of treating cancer, including administering to a sub-
ject an effective amount of a bryostatin agent to enhance cell surface
antigen or neoantigen presentation on target cells of the subject, and
administering to the subject a therapeutically effective amount of
a therapeutic agent that specifically binds the cell surface antigen
to treat the subject for cancer. Aspects of the subject methods also
include use of the bryostatin agents to sensitize the target cells to
clearance by the subject's immune system.

[Continued on next page]

Published:

— with international search report (Art. 21(3))